食物中存在的黄酸盐对1型糖尿病实验小鼠骨系统的影响
Sylwia Klasik-Ciszewska1, Piotr Londzin1, Kacper Grzywnowicz1
1Department of Pharmacology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland.
Nutrients
|January 25, 2025
概括
氨酸对1型糖尿病 (T1D) 的老鼠的骨健康有非常有限的积极影响. 虽然T1D恶化了骨强度,但素补充剂在一些骨参数中略有改善.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 植物衍生化合物可能为糖尿病并发症,包括骨问题提供健康益处.
- 素是一种天然的黄类化合物,具有抗氧化,抗炎和抗糖尿病的特性.
- 1型糖尿病 (T1D) 对骨代谢和强度产生负面影响.
研究的目的:
- 为了评估辛对实验诱导的1型糖尿病的老鼠骨系统的影响.
- 评估辛在减轻糖尿病引起的骨损伤方面的潜力.
主要方法:
- 在雄性Wistar大鼠中,使用链毒素诱导了1型糖尿病.
- 克里辛在每天50或100毫克/公斤口服四周,从诱导后两周开始.
- 分析了骨循环标记,骨质量,密度,矿化,机械特性和组织形态测量.
主要成果:
- 与健康对照组相比,1型糖尿病显著损害骨代谢,骨强度降低.
- 在糖尿病大鼠中,施用素导致特定骨参数的轻微改善.
- 素所观察到的作用是有限的,只显示了轻微的益处.
结论:
- 在1型糖尿病的背景下,氨酸对骨系统具有非常有限的有利影响.
- 可能需要进一步的研究来探索辛在糖尿病骨病中的全部潜力和机制.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Oral Hypoglycemic Agents: Biguanides and Glitazones
164
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
164
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141


